Novartis to launch DTP platform for Cosentyx in US
Through the new DTP platform, Novartis will make Cosentyx available to patients at a price that reflects the average savings typically retained by insurers and pharmacy benefit managers
Through the new DTP platform, Novartis will make Cosentyx available to patients at a price that reflects the average savings typically retained by insurers and pharmacy benefit managers
Pfizer will participate in TrumpRx.gov, a direct-to-patient purchasing platform offering discount up to 85%
Eliquis (apixaban) available at more than 40 per cent discount; Sotyktu to be offered at more than 80 per cent discount to current list price
The platform is being introduced to expand access to treatments for people living with chronic conditions
Expanded capabilities that continue to push the boundaries of innovation—advancing drug delivery solutions for patients, customers, and consumers around the world
BIL also holds an option to increase its equity stake by an additional 15%
The association called for an end to the constant issuance of regulatory circulars that make operations unpredictable and capital-intensive.
Alkem's Pertuza is an affordable, indigenously-developed and manufactured biosimilar of pertuzumab
Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada
Subscribe To Our Newsletter & Stay Updated